Analysts’ Recent Ratings Changes for First Tracks Biotherapeutics (TRAX)

Several analysts have recently updated their ratings and price targets for First Tracks Biotherapeutics (NASDAQ: TRAX):

• 7/28/2026 – First Tracks Biotherapeutics had its price target raised by Wells Fargo & Company from $30.00 to $55.00. They now have an “overweight” rating on the stock.
• 7/28/2026 – First Tracks Biotherapeutics had its price target raised by Wedbush from $30.00 to $60.00. They now have an “outperform” rating on the stock.
• 7/21/2026 – First Tracks Biotherapeutics had its price target raised by Barclays PLC from $40.00 to $48.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – First Tracks Biotherapeutics had its price target raised by HC Wainwright from $30.00 to $44.00. They now have a “buy” rating on the stock.
• 7/8/2026 – First Tracks Biotherapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
• 6/8/2026 – First Tracks Biotherapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $30.00 price target on the stock.
• 6/8/2026 – First Tracks Biotherapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $30.00 price target on the stock.